People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avenzo Therapeutics, Inc. | — | Biotechnology | Series D+ | $270.6M | $355.3M | 2025 |
| Adverum Biotechnologies, Inc. | — | Biotechnology | Series D+ | $198.6M | $1.6B | 2024 |
| Turnstone Biologics Corp. | — | Biotechnology | Series C | $122.1M | $2.2B | 2019 |
Patrick Machado at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Patrick Machado on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Jerel Davis | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Judith Li | 1 | 8 |
| Simeon George | 1 | 8 |
| Steven Schwartz | 1 | 6 |
| Laurent Fischer | 1 | 4 |
| Stefan Larson | 1 | 4 |
| Mark Blumenkranz | 1 | 3 |
| Michael Rome | 1 | 3 |
| John McLaughlin | 1 | 3 |
| Robert Gould | 1 | 3 |
| Garry Nicholson | 1 | 3 |
| Jane Henderson | 1 | 2 |
| Athena Countouriotis | 1 | 2 |
| Thomas Chalberg | 1 | 2 |
| Mark S. Blumenkranz | 1 | 2 |
| Paul Wachter | 1 | 2 |
| Mohammad Hirmand | 1 | 2 |
| Sammy Farah | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.